1. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2‐year results of a randomized clinical trial. Issue 11 (17th June 2013) Authors: Bode, B. W.; Buse, J. B.; Fisher, M.; Garg, S. K.; Marre, M.; Merker, L.; Renard, E.; Russell‐Jones, D. L.; Hansen, C. T.; Rana, A.; Heller, S. R. Journal: Diabetic medicine Issue: Volume 30:Issue 11(2013:Nov.) Page Start: 1293 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Insulin degludec improves long‐term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal‐bolus insulin therapy. Issue 2 (27th November 2014) Authors: Hollander, P.; King, A. B.; Del Prato, S.; Sreenan, S.; Balci, M. K.; Muñoz‐Torres, M.; Rosenstock, J.; Hansen, C. T.; Niemeyer, M.; Garber, A. J. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 2(2015:Feb.) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗